TABLE 2.
Treatment preceding the start of Janus kinases (JAK) inhibitors.
| Treatment | N (%) |
| Glucocorticoids (GCs) | |
| Topical GCs | 10 (14 eyes)–83.3% |
| Local/regional GCs injections | 2 (3 eyes)–16.7% |
| Systemic GCs | 9 (75%) |
| Oral GCs | 9 (75%) |
| Endovenous GCs | 1 (8.3%) |
| cDMARDs | |
| Methotrexate | 7 (58.3%) |
| Azathioprine | 4 (33.33%) |
| Cyclosporine A | 4 (33.33%) |
| Sulfasalazine | 3 (25%) |
| bDMARDs | |
| Adalimumab | 10 (83.3%) |
| Golimumab | 6 (50%) |
| Infliximab | 5 (41.7%) |
| Etanercept | 2 (16.7%) |
| Certolizumab | 2 (16.7%) |
| Tocilizumab | 1 (6.25%) |
bDMARDs, biologic disease modifying anti-rheumatic drugs; cDMARDs, conventional disease modifying anti-rheumatic drugs; GCs, glucocorticoids; n, number.